Cidara Therapeutics Inc.
Cidara Therapeutics Reports Q3 2025 Financial Results and Corporate Update
Summary
Cidara Therapeutics, Inc. reported financial results for the third quarter of 2025 and provided updates on its non-vaccine influenza preventative therapeutic, CD388. The company's cash balance increased significantly to $476.5 million. Key highlights include the enrollment and dosing of the first patients in the Phase 3 ANCHOR study, a BARDA award for CD388, and the FDA granting Breakthrough Therapy designation to CD388. The company expects to achieve target enrollment of 6,000 participants by December 2025. Acquired in-process R&D expenses amounted to $45.0 million for the quarter, related to a milestone payment under the Janssen License Agreement.
Profitelligence Alerts
Get alerts for CDTX
Be first to know when Cidara Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Official SEC Documents
Advertisement